宫颈鳞癌和癌前病变中eIF-4E表达及其与HPV16/18感染的关系

目的探讨真核翻译启始因子eIF-4E在宫颈鳞癌和癌前病变中的表达规律及其与人乳头瘤病毒（HPV）感染之间的关系。方法采用免疫组化ABC法和原位杂交技术检测eIF-4E蛋白和HPV16／18DNA在10例正常宫颈鳞状上皮,29例低级别上皮内瘤变（CIN1级）,31例高级别上皮内瘤变（CIN2、3级）和31例宫颈鳞癌中的表达。结果eIF4E在正常宫颈鳞状上皮中呈阴性表达,随着上皮病变级别升高,表达逐渐增强：低级别〈高级别上皮内瘤变〈宫颈鳞癌（P〈0．05）,且在宫颈鳞癌中表达更强;HPV16／18DNA在四组中的阳性表达率,除高级别上皮内瘤变和宫颈鳞癌两组之间没有差别（均为96．8％）以外,其余各组之间差异均有显著性（P〈0．01）;在低级别、高级别上皮内瘤变和宫颈鳞癌三组中eIF-4E蛋白表达和HPV感染均呈明显正相关（P〈0．01）。结论宫颈鳞癌的发生与eIF-4E蛋白表达及HPV16／18感染密切相关;二者在宫颈鳞癌的发病机制中可能起着协同作用。     

脱落细胞人乳头瘤病毒L1壳蛋白的半定量检测有助于宫颈病变的鉴别诊断

目的研究人乳头瘤病毒L1(HPV L1)壳蛋白的表达量与宫颈上皮内瘤变的关系及其临床意义。方法采用免疫细胞化学方法检测153例宫颈脱落细胞中HPV L1壳蛋白的表达,用ImagePro Plus图像分析软件对HPV L1壳蛋白阳性单位(PU)进行半定量检测,并以宫颈活检的组织病理学结果为确诊标准。结果 HPV L1壳蛋白PU在宫颈细胞学分类为正常/炎症、未知意义的不典型鳞状细胞(ASCUS)、低级别上皮内瘤变、高级别上皮内瘤变组别中定量结果依次为46.87±24.46、27.23±24.30、24.10±22.45、9.36±19.82,差异具有统计学意义(P0.01);其PU在组织学正常/炎症、低级别上皮内瘤变、高级别上皮内瘤变分组中分别为41.30±26.66、24.84±22.18、8.69±19.20,差异具有统计学意义(P0.01);HPV L1壳蛋白PU与宫颈疾病的严重程度在细胞学分组和组织学分组中均呈负相关(r=-0.458,r=-0.441,P0.01)。在高危型HPV感染的细胞中,HPV L1壳蛋白PU在HPV16、HPV18中的含量低于其他分型,差异具有统计学意义(P0.01),HPV L1壳蛋白PU与年龄无关(P0.05)。结论半定量分析HPV L1壳蛋白在诊断宫颈癌前病变中具有一定的指导作用。     

The relationship between the HR-HPV load and cervical lesions in Chaozhou area

目的 探讨高危型人乳头瘤病毒(high risk human papillomavirus,HR-HPV)载量与宫颈病变级别之间的关系.方法 采用RT-PCR对农村35～60岁女性进行HR-HPV DNA定量检测并记录CT值,2 731例阳性者再进行核酸分子快速导流杂交分型技术(HybriMax)和液基薄层细胞学(thinprep liquid-based cytologic test,LCT)检查;对低级别鳞状上皮内病变(low grade squamous intraepithelial lesion,LSIL)及以上病变行阴道镜下组织病理学活检.根据LCT及病理活检结果按病变级别分成5组:无上皮内瘤变或恶性病变(non-squamous intraepithelial lesion or neoplasia,NILM)、未明确诊断意义的不典型鳞状上皮细胞(atypical squamous cells of undetermined significance,ASCUS)、LSIL、高级别鳞状上皮内病变(high grade squamous intraepithelial lesion,HSIL)和鳞状细胞癌(squamous cell cacinoma,SCC).在同级别宫颈病变中,按照HPV感染的类型分为4组:HPV52、HPV16、HPV58和多重HPV感染.采用方差分析的方法对各组平均CT值进行统计分析.结果 随宫颈病变级别的升高,CT均值降低,5组CT均值间差异均具有显著性(P＜0.05).在同级别宫颈病变中,NILM组HPV58和多重HPV差异有显著性(P＜0.05),ASCUS组HPV16和多重HPV差异有显著性,其余病变级别各HPV感染组间差异均无显著性(P＞0.05).结论 HR-HPV载量与宫颈病变级别呈正相关,高HR-HPV载量是影响宫颈病变级别的危险因素.     

子宫颈癌、子宫颈上皮内病变组织中SIRT1、HPV 16/18E6的表达及其意义

目的检测子宫颈癌及癌前病变中SIRT1的表达情况,探讨其与临床病理特征的关系。同时检测早期癌蛋白中HPV16/18E6的表达,分析两者的相关性。方法应用免疫组化En Vision法检测30例子宫颈炎、100例子宫颈上皮内病变(高级别、低级别各50例)、30例子宫颈鳞状细胞癌组织中SIRT1和HPV 16/18E6的表达。结果子宫颈癌组织中SIRT1阳性率为93.33%(28/30),高于子宫颈炎组织(13.33%,4/30),差异有统计学意义(P0.05)。子宫颈高级别上皮内病变SIRT1阳性率(88%,44/50)高于低级别上皮内病变(14%,7/50),差异有统计学意义(P0.05)。但高级别上皮内病变与子宫颈癌SIRT1阳性率差异无统计学意义(P0.05);低级别上皮内病变与子宫颈炎中SIRT1阳性率差异无统计学意义(P0.05)。在子宫颈癌中,SIRT1的阳性率与临床分期和组织学分级有关,晚期、分化差的子宫颈癌阳性率高于早期、分化好的子宫颈癌,差异有统计学意义(P0.05)。在子宫颈癌中SIRT1的阳性率(93.33%,28/30)高于HPV 16/18E6(30%,9/30),在子宫颈高级别上皮内病变中SIRT1的阳性率(88%,44/50)高于HPV 16/18E6(28%,14/50),但在低级别上皮内病变中SIRT1的阳性率(14%,7/50)低于HPV 16/18E6(36%,18/50),两者差异有统计学意义(P0.05)。结论 SIRT1的阳性率随着病变程度增加而升高,提示SIRT1与细胞恶性转变有关,其过表达可能促进上皮向高级别内病变乃至子宫颈癌进展。     

潮州地区高危型人乳头瘤病毒载量与宫颈病变的关系

目的探讨高危型人乳头瘤病毒(high risk human papillomavirus,HR-HPV)载量与宫颈病变级别之间的关系。方法采用RT-PCR对农村35～60岁女性进行HR-HPV DNA定量检测并记录CT值,2 731例阳性者再进行核酸分子快速导流杂交分型技术(HybriMax)和液基薄层细胞学(thinprep liquid-based cytologic test,LCT)检查;对低级别鳞状上皮内病变(low grade squa-mous intraepithelial lesion,LSIL)及以上病变行阴道镜下组织病理学活检。根据LCT及病理活检结果按病变级别分成5组:无上皮内瘤变或恶性病变(non-squamous intraepithelial lesion or neoplasia,NILM)、未明确诊断意义的不典型鳞状上皮细胞(atypi-cal squamous cells of undetermined significance,ASCUS)、LSIL、高级别鳞状上皮内病变(high grade squamous intraepithelial lesion,HSIL)和鳞状细胞癌(squamous cell cacinoma,SCC)。在同级别宫颈病变中,按照HPV感染的类型分为4组:HPV52、HPV16、HPV58和多重HPV感染。采用方差分析的方法对各组平均CT值进行统计分析。结果随宫颈病变级别的升高,CT均值降低,5组CT均值间差异均具有显著性(P<0.05)。在同级别宫颈病变中,NILM组HPV58和多重HPV差异有显著性(P<0.05),ASCUS组HPV16和多重HPV差异有显著性,其余病变级别各HPV感染组间差异均无显著性(P>0.05)。结论 HR-HPV载量与宫颈病变级别呈正相关,高HR-HPV载量是影响宫颈病变级别的危险因素。     

分化型外阴上皮内瘤变的研究进展

外阴鳞状细胞癌约占外阴恶性肿瘤的80%, 高级别外阴鳞状上皮内瘤变是外阴鳞状细胞癌的癌前病变, 按照病理机制可分为普通型高级别外阴鳞状上皮内瘤变, 与人乳头状瘤病毒(HPV)感染密切相关, 主要以HPV 16型感染为多见;另一类为HPV不相关的上皮内瘤变, 这类癌前病变的病理发生机制目前还在研究中。局部慢性非感染性炎症性外阴皮肤病, 如棘层肥厚性皮肤病的慢性单纯性苔藓和苔藓样皮肤病的硬化性苔藓等组织学表现可见于这类病变。根据p53表达的最新研究, HPV不相关的上皮内瘤变可分为:p53突变型, 即分化型外阴上皮内瘤变(differentiated-type vulvar squamous intraepithelial neoplasia, dVIN)和p53野生型, 即分化性外生型外阴上皮内病变和外阴棘皮病伴分化改变。以上所述上皮内瘤变或上皮内病变不仅在临床表现上不同, 早期病理变化细微, 在分子发生机制上也截然不同。因此, 此类病变在病理诊断和临床处理方面均具挑战。本文阐述并总结了目前dVIN的国内外病理研究进展和临床意义及临床靶向治疗的选择。     

原位核酸分子杂交技术检测宫颈鳞状上皮病变HPV感染

目的:观察宫颈鳞状上皮病变过程中HPV6/11、HPV16/18的表达,探讨其测定的临床意义.方法:选择病理诊断为宫颈慢性炎症50例、鳞状上皮乳头状瘤样增生30例、尖锐湿疣30例、上皮内瘤变89例、鳞癌50例共249例石蜡包埋标本,应用原位核酸分子杂交技术对其进行HPV6/11,HPV16/18检测.结果:慢性炎症组HPV6/11阳性表达4%,HPV16/18阳性表达0%;乳头状瘤样增生组HPV6/11阳性表达10%,HPV16/18阳性表达3.3%;尖锐湿疣组HPV6/11阳性表达93.3%,HPV16/18阳性表达23.3%;CIN组中Ⅰ级HPV6/11阳性表达48.9%,HPV16/18阳性表达42.2%;Ⅱ级HPV6/11阳性表达39.1%,HPV16/18阳性表达69.6%;Ⅲ级HPV6/11阳性表达9.5%,HPV16/18阳性表达66.7%;鳞癌组HPV6/11阳性表达6%,HPV16/18阳性表达82%.结论:应用原位核酸分子杂交技术检测宫颈鳞状上皮病变细胞的HPV6/11、HFV16/18,为临床早期诊断、鉴别诊断及评估预后提供可靠的理论依据.     

p16INK4a在宫颈细胞学鳞状上皮内瘤变中的意义

目的探讨p16^INK4a的表达在宫颈细胞学中鳞状上皮内瘤变中的意义及其与人乳头状瘤病毒（HPV）型别之间的关系。方法对88例经活检证实的液基细胞学标本[包括20例慢性宫颈炎、18例低度鳞状上皮内瘤变（LSIL）、34例高度鳞状上皮内瘤变（HSIL）及16例鳞状上皮细胞癌（SCC）],分别用免疫细胞化学（EnVision方法）检测其p16^INK4a的表达,并对所有标本用聚合酶链反应（PCR）方法检测HPV型别（包括HPV16、18、31、33、35、39、45、51、52、53、56、58、59、66、68、6、11、42、43及44型）。结果p16^INK4a在慢性宫颈炎组呈阴性,在LSIL、HSIL及SCC组的表达率分别为27．8％、100％及100％,LSIL、HSIL及SCC组p16^INK4a的表达均显著高于慢性宫颈炎组（P〈0．01）;p16^INK4a在高危型HPV感染组的表达率（96．4％）显著高于低危型HPV感染组（7．7％）,差异有统计学意义（t=4．32,P〈0．01）。结论p16^INK4a是一种敏感性较高,特异性较好的标记物,可以识别与高危型HPV有关的非典型鳞状上皮细胞。     

宫颈脱落细胞中miR-424和CUL2 mRNA表达对宫颈HPV16持续感染的预测价值

目的 研究宫颈脱落细胞中微小RNA-424(miR-424)和枯灵素2(CUL2)信使RNA(mRNA)表达水平对宫颈人乳头瘤病毒(HPV)16持续感染的预测价值。方法 选取2020年1月至2021年11月在邯郸市中心医院宫颈液基细胞学检查正常的259例宫颈HPV16感染者为研究对象，随访1年后复查，HPV16仍是阳性者归为HPV16持续感染组(136例),HPV16转为阴性者归为HPV16非持续感染组(123例)。对宫颈HPV16持续感染者在复查当日以组织病理学诊断结果进行分组：52例慢性宫颈炎症患者(宫颈炎症组),61例宫颈上皮内瘤变者(上皮瘤变组),23例宫颈鳞癌患者(宫颈鳞癌组)。采用荧光定量PCR法检测宫颈脱落细胞中miR-424和CUL2 mRNA表达水平，Pearson法分析HPV16持续感染者宫颈脱落细胞中miR-424和CUL2 mRNA的相关性，受试者工作特征曲线评价宫颈脱落细胞中miR-424和CUL2 mRNA表达水平对宫颈HPV16持续感染的预测价值。结果 与HPV16非持续感染组相比，HPV16持续感染组宫颈脱落细胞中miR-424表达水平较低，CUL2 m...     

人乳头状瘤病毒阴性的宫颈癌及其癌前病变中p16INK4A蛋白表达和DNA倍体分析

目的探讨人乳头状瘤病毒（HPV）感染阴性的宫颈癌及其癌前病变中p16^INK4A蛋白表达和DNA倍体分析的临床病理学意义。方法应用PCR方法筛查出HPV感染阴性的20例慢性宫颈炎、20例宫颈上皮内瘤变（CIN）、3例宫颈腺上皮内瘤变（CGIN）、38例浸润性鳞状细胞癌（鳞癌）和15例浸润性腺癌作为研究对象。应用免疫组织化学（LSAB）染色方法检测p16^INK4A蛋白在这些病变组织中的表达,并结合流式细胞仪DNA倍体分析探讨HPV阴性的宫颈癌的早期诊断和预后判定。结果p16^INK4A蛋白特异性地表达在CIN和CGIN病变、鳞癌以及腺癌细胞的胞核和胞质中,而在正常鳞状上皮和腺上皮中没有任何阳性表达信号。另外,DNA异倍体在浸润性鳞癌和腺癌中的表达率明显高于CIN病变组（P〈0．01）。在有淋巴结转移的浸润癌中DNA异倍体存在的百分率高于无淋巴结转移组,但尚未发现差异有统计学意义。在8例p16^INK4A表达阴性的浸润性鳞癌中有2例表现为DNA异倍体。结论p16^INK4A蛋白检测可以作为HPV感染阴性的宫颈鳞癌及腺癌的早期诊断指标,结合DNA倍体分析将对宫颈恶性肿瘤的诊断有重要的辅助意义。     

宫颈癌中α-enolase表达及其与HPV感染的关系

目的探讨烯醇化酶-α(α-enolase)蛋白在宫颈鳞癌中的表达及其与HPV感染的关系。方法应用免疫组化PV-9000两步法检测30例慢性宫颈炎、61例宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)和70例宫颈鳞癌组织中α-enolase蛋白的表达,同时应用基因芯片技术检测70例宫颈鳞癌中HPV感染情况。结果 (1)α-enolase蛋白表达于细胞质和(或)胞核中。在慢性宫颈炎、CIN和宫颈癌中,α-enolase蛋白在胞质表达的阳性率分别为4.17%(1/24)、18.5%(10/54)和54.3%(38/70),表达依次增强(P=0.000)。(2)宫颈癌中HPV总感染率为97.1%(68/70),共检出8种HPV基因型,分别为HPV16、18、58、31、52、59、66、68,构成比为80.0%、14.3%、4.3%、4.3%、2.9%、2.9%、1.43%、1.43%。双重感染10例,占14.3%。HPV16、18为主要致病基因型。(3)宫颈癌中α-enolase蛋白表达的定位与HPV16/18感染呈正相关(r=0.340,P=0.012)。结论宫颈鳞癌中α-enolase蛋白表达与HPV16/18感染密切相关,二者在宫颈鳞癌的发生过程中可能起着协同作用。     

人乳头状瘤病毒不同型别与宫颈病变的相关性研究

目的探讨人乳头状瘤病毒（ＨＰＶ）不同型别与宫颈病变性质的关系。方法应用ＰＣＲ技术和原位杂交方法对６１例宫颈上皮内瘤（ＣｅｒｖｉｃａｌｉｎｔｒａｅｐｉｔｈｅｌｉａｌＮｅｏｐｌａｓｉａＣＩＮ）和１２例宫颈鳞癌（ＳＣＣ）进行ＨＰＶ６Ｂ／１１、１６、１８ＤＮＡ检测。结果ＰＣＲ检测结果显示ＨＰＶ６、１１主要分布于低度鳞状上皮内病变（６１９％）和一部分ＣＩＮⅡ中（２０％），而在ＣＩＮⅢ和ＳＣＣ中检测不到；ＨＰＶ１６、１８的检出率随ＣＩＮ级别增高而增加，在ＳＣＣ中高达８３３％。原位杂交结果显示在低度鳞状上皮内病变中，地高辛（Ｄｉｇ）标记的ＨＰＶ６Ｂ／１１、１６、１８ＤＮＡ杂交物质在核中均呈细颗粒状，为“游离型”。上述杂交阳性信号形态亦出现于ＣＩＮⅡ的所有ＨＰＶ６Ｂ／１１及部分ＨＰＶ１６、１８型感染中，而ＣＩＮⅢ和宫颈鳞癌及部分ＣＩＮⅡ中，其杂交阳性信号均为非颗粒状的“整合型”。结论低度鳞状上皮内病变是以ＨＰＶ６、１１低危型为主的多型别病毒的繁殖性感染，ＣＩＮⅢ和宫颈鳞癌为ＨＰＶ１６、１８高危型病毒的整合型感染，而在ＣＩＮⅡ中存在着ＨＰＶ６，１１和ＨＰＶ１６，１８的繁殖性感染及ＨＰＶ１６，１８的整合型感染     

子宫颈癌中Hedgehog信号通路蛋白表达与人乳头状瘤病毒16型感染的关系

目的 探讨Hedgehog(Hh)信号通路蛋白在宫颈癌及其癌前病变中的临床病理学意义,并分析其与人乳头状瘤病毒(HPV)16型感染的关系.方法 32例正常宫颈上皮、71例宫颈上皮内瘤变(CIN;CIN Ⅰ 28例,CIN Ⅱ 18例,CIN Ⅲ25例)和80例宫颈鳞状细胞癌共183例选自延边大学医院、延边妇幼保健院和延边肿瘤医院病理科存档蜡块.应用PCR技术检测上述组织中HPV16型的感染情况,并应用Shh、Ihh、Ptch和Smo 4种Hh信号通路蛋白抗体、组织芯片和免疫组织化学EnVision法检测Hh信号通路蛋白在上述病变组织中的表达情况.结果 Shh、Ihh、Ptch和Smo在正常宫颈黏膜上皮中为弱阳性,而在宫颈癌和CIN Ⅲ中呈强阳性,其表达率均显著高于正常宫颈黏膜上皮(P均<0.05).80例官颈癌标本中HPV16阳性率是77.5%(62/80),而且Shh蛋白的强阳性率在HPV16型阳性的宫颈癌组织中显著高于HPV16阴性组(P<0.05).结论 Hh信号通路蛋白过表达可以作为宫颈癌及其癌前病变的早期辅助诊断指标并有望成为宫颈癌靶向治疗的新靶点,而且Shh蛋白的过表达与HPV16型感染密切相关.     

Human papillomavirus genotyping by oligonucleotide microarray and p16 expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women

For evaluating the diagnostic significance of p16(INK4A) over-expression in the uterine cervical intraepithelial neoplasm and in invasive carcinoma, human papillomavirus (HPV) was detected and genotyped by oligonucleotide microarray in archival tissues of 117 cervical specimens, including 47 invasive squamous cell carcinomas (SCC), 30 cases of cervical intraepithelial neoplasia (CIN), 20 adenocarcinomas, and 20 cases of non-neoplastic cervix. The expression of p16(INK4A) protein was immunohistochemically studied in these cases and in five HPV-positive and one HPV-negative cervical cancer cell lines. HPV was detected in 50% of CIN, 61.7% of SCC, and 45.5% of adenocarcinomas. p16(INK4A) expression was seen in all 20 cases of adenocarcinoma, 78.7% (37/47) of SCC, and 96.7% (29/30) of CIN, but not in any cases of the non-neoplastic cervix. There was no difference in p16(INK4A) expression between the HPV-positive and HPV-negative cervical lesions. All HPV-positive and -negative cervical cancer cell lines expressed p16(INK4A) protein. In conclusion, the presence of p16(INK4A) expression in cervical squamous and glandular epithelium indicates the existence of dysplasia or malignancy in the uterine cervix, regardless of HPV infection.     

nm23-H1 protein immunoreactivity in intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix

Differences In the Immunohlstochemlcal expression of the 17 kDa protein encoded by the human nm23-H1 gene were studied In premallgnant lesions and Invasive squamous cell carcinoma (SCC) (N = 8) of the cervix using routine streptavldln-blotln Immunohistochemlstry and a polyclonal antibody to the nm23-H1 protein. The premalignant lesions were kollocytic atypla due to wart virus Infection (N = 5), low-grade cervical intraepithelial neoplasia (CIN) (N = 7) and high-grade CIN (N = 7). The carcinomas were either moderately (N = 3) or poorly differentiated (N = 5). The non-neoplastlc controls were normal squamous epithelium from cases with uterine prolapse (N = 7) and normal squamous epithelium not affected by the Infective or neoplastic areas of some of the cases with wart virus Infection (N = 2) and carcinoma (N = 2). Moderate to strong cytoplasmic and, occasionally, nuclear Immunostainlng for the nm23-H1 protein was seen in all cells above the basal layer of the normal squamous epithelium. However, most of the cervical SCC show a relative reduction in nm23-H1 immunoreactivity (7/8 cases; 88%). This difference In nm23-H1 expression was statistically significant (P = 0.0006; Chi-squared test with continuity correction). All of the cases with wart virus Infection (N = 5; 100%) displayed moderately strong nm23-H1 immunostaining throughout the squamous epithelium except for the basal layer where no staining was observed. The cases that had low-grade squamous dysplasia of the cervix (CIN Ml) (N = 7; 100%) also displayed moderate to strong nm23-H1 Immunoreactivity In the epithelium except for the basal layer (CIN I) or the lower two-thirds of the epithelium (CIN II). nm23-H1 Immunoreactivity was either absent or was significantly reduced in all of the high-grade CIN (CIN III) cases (At = 7; 100%) in which only the non-dysplastJc superficial third of the squamous epithelium displayed nm23-H1 immunolabeling. The difference in nm23-H1 expression between low-grade and high-grade CIN cases was statistically significant (P = 0.0013; Chi-squared test with continuity correction). Similarly, the difference between low-grade CIN and SCC cases in the expression of nm23-H1 was also significant (P = 0.0041; Chi-squared test with continuity correction). However, no statistically significant difference in nm23-H1 immunoreactivity was found between cases of high-grade CIN and SCC. In conclusion, nm23-H1 protein immunoreactivity is reduced in high-grade CIN and cervical SCC but not in low-grade CIN. These findings suggest that reduced expression of the protein may be Important early in the sequential development of cervical squamous neoplasia.     

细胞周期素D1和抗原Ki-67在宫颈上皮内瘤样病变和宫颈鳞癌的表达及与人乳头瘤病毒感染转归的关系

目的 研究细胞周期素D1(cyclin D1)、抗原Ki-67在宫颈上皮内瘤样病变(CIN)和宫颈鳞癌发生发展中作用及其与人乳头瘤病毒(HPV)感染转归的关系.方法 2002年1月至2006年12月广州医学院第一附属医院HPV阳性患者104例,分2组:(1)研究组:82例,即病理确诊CIN Ⅰ组17例、CINⅡ组19例、CINⅢ组23例、宫颈鳞癌组23例.(2)对照组:柱状上皮异位22例.应用EnVision法检测宫颈病变组织中cyclin D1、Ki-67蛋白的表达,杂交捕获试验检测宫颈分泌物或阴道残端中HPV感染情况,随访各组患者术后1年内的HPV变化.结果 (1)cyclin D1在各组宫颈组织细胞核内均有表达.其阳性率CINⅢ组[82.61%(19/23)]、宫颈鳞癌组[86.96%(20/23)]与对照组[27.27%(6/22)]、CINⅠ组[58.82%(10/17)]比较,差异有统计学意义(P<0.05),在宫颈鳞癌组与CINⅡ组[68.42%(13/19)]阳性率比较差异有统计学意义(P<0.05).(2)Ki-67在各组宫颈组织细胞核内均有表达,其对照组阳性率[31.82%(7/22)]与CINⅢ组[86.96%(20/23)]、宫颈鳞癌组[91.30%(21/23)]比较差异有统计学意义(P<0.05),而在宫颈鳞癌组与CINⅠ组[58.82%(10/17)]、CIN Ⅱ组[63.16%(12/19)]比较差异有统计学意义(P<0.05).(3)术后1年内各组HPV的转阴率分别与cyclin D1、Ki-67的表达强度呈负相关(rs=-0.299,rs=-0.367,P<0.05).结论 cyclinD1和Ki-67在CIN和宫颈鳞癌的细胞增殖活动中起作用,且两者可能与HPV感染转阴率有关.     

Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy

It has been recognized that human papillomavirus infection is the major causal factor for high-grade cervical lesions. The aim of the study was to evaluate the relationship between HPV 16 and 18 viral loads and cervical status in different age strata. A duplex real time PCR method was devised to determine HPV 16 and 18 viral load per million of human cells using an in house plasmidic construct as a standard of quantification. The 151 cervical scrapes were collected before colposcopic examination from either abnormal cervico-vaginal smear (group 1, 97 patients) or from post treatment clinical follow-up (group 2, 54 patients). In women aged 30-40, the HPV16 viral loads were significantly higher in high-grade squamous intraepithelial lesion than in low-grade squamous intraepithelial lesion in both groups and HPV18 in group 1. In women aged 20-30 of group 1, high HPV viral load was associated in few cases with high-grade squamous intraepithelial lesion or low-grade squamous intraepithelial lesion, and surprisingly in some patients with normal cervix. HPV 16 and 18 viral loads are related to the severity of cervical lesion, and may be useful in the clinical management of cervical lesions. A specific follow-up may be useful for those with high viral load despite normal cervix.     

Cathepsin E expression by normal and premalignant cervical epithelium.

We have investigated the expression of the aspartic proteinase cathepsin E and HLA-DR and the presence of HPV16 in normal squamous epithelium (n = 8) and low-grade (n = 21) and high-grade (n = 14) intraepithelial squamous lesions of the uterine cervix. Immunohistochemistry of cervical biopsies revealed that up-regulation of cathepsin E expression was related to increasing severity of the cervical intraepithelial neoplasia (CIN). Up-regulation of protein was associated with increased message as assessed by in situ hybridization. Langerhans cells and the majority of koilocytes did not express detectable cathepsin E levels. Although there was also an up-regulation of HLA-DR expression by cervical keratinocytes in cervical intraepithelial neoplasia lesions, as determined by immunohistochemistry, no significant correlation was found between HLA-DR and cathepsin E expression in these lesions; neither was expression of cathepsin E correlated to the presence of HPV16, detected by polymerase chain reaction. The expression of cathepsin E, an aspartic proteinase that is reported to play a role in antigen processing for presentation by class II major histocompatibility complex molecules, is associated with cellular dedifferentiation in cervical intraepithelial neoplasia.     

Morphoproteomic Evidence of Constitutively Activated and Overexpressed mTOR Pathway in Cervical Squamous Carcinoma and High Grade Squamous Intraepithelial Lesions

Human papilloma virus (HPV) infection of the uterine cervix is linked to the pathogenesis of cervical cancer. Preclinical in vitro and in vivo studies using HPV-containing human cervical carcinoma cell lines have shown that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, erlotinib, can induce growth delay of xenografts. Activation of Akt and mTOR are also observed in cervical squamous cell carcinoma and, the expression of phosphorylated mTOR was reported to serve as a marker to predict response to chemotherapy and survival of cervical cancer patients. Therefore, we investigated: a) the expression level of EGFR in cervical squamous cell carcinoma (SCC) and high-grade squamous intraepithelial lesions (HSIL) versus non-neoplastic cervical squamous epithelium; b) the state of activation of the mTOR pathway in these same tissues; and c) any impact of these signal transduction molecules on cell cycle. Formalin-fixed paraffin-embedded tissue microarray blocks containing 20 samples each of normal cervix, HSIL and invasive SCC, derived from a total of 60 cases of cervical biopsies and cervical conizations were examined. Immunohistochemistry was utilized to detect the following antigens: EGFR; mTOR pathway markers, phosphorylated (p)-mTOR (Ser2448) and p-p70S6K (Thr389); and cell cycle associated proteins, Ki-67 and S phase kinase-associated protein (Skp)2. Protein compartmentalization and expression were quantified in regard to proportion (0-100%) and intensity (0-3+). Mitotic index (MI) was also assessed. An expression index (EI) for pmTOR, p-p70S6K and EGFR, respectively was calculated by taking the product of intensity score and proportion of positively staining cells. We found that plasmalemmal EGFR expression was limited to the basal/parabasal cells (2-3+, EI = 67) in normal cervical epithelium (NL), but was diffusely positive in all HSIL (EI = 237) and SCC (EI 226). The pattern of cytoplasmic p-mTOR and nuclear p-p70S6K expression was similar to that of EGFR; all showed a significantly increased EI in HSIL/SCC versus NL (p<0.02). Nuclear translocation of p-mTOR was observed in all SCC lesions (EI = 202) and was significantly increased versus both HSIL (EI = 89) and NL (EI = 54) with p<0.015 and p<0.0001, respectively. Concomitant increases in MI and proportion of nuclear Ki-67 and Skp2 expression were noted in HSIL and SCC. In conclusion, morphoproteomic analysis reveals constitutive activation and overexpression of the mTOR pathway in HSIL and SCC as evidenced by: increased nuclear translocation of pmTOR and p-p70S6K, phosphorylated at putative sites of activation, Ser2448 and Thr389, respectively; correlative overexpression of the upstream signal transducer, EGFR, and increases in cell cycle correlates, Skp2 and mitotic indices. These results suggest that the mTOR pathway plays a key role in cervical carcinogenesis and targeted therapies may be developed for SCC as well as its precursor lesion, HSIL.     

环氧化酶-2及血管内皮生长因子在宫颈癌及其癌前病变中的表达

目的探讨环氧化酶-2（cyclooxygenenase-2,COX-2）的表达与宫颈癌发生的关系以及COX-2与血管内皮生长因子vascular endothelial growth factor,VEGF）表达的关系。方法采用免疫组化（S-P）法检测20例正常宫颈、26例低度宫颈上皮内瘤变（cervical intraepithelial neoplasia,CIN;CIN Ⅰ）、28例高度CIN（CIN Ⅱ／Ⅲ）、25例宫颈癌组织中COX-2、血管内皮生长因子vascular endothelial growth faclor,VEGF）的表达,并分析COX-2与VEGF及高危HPV感染的关系。结果在正常宫颈、低度CIN、高度CIN、宫颈癌中COX-2的表达率分别为0、23．08％、57．14％、84％,VEGF的表达率分别为5％、30．77％、60．71％、88％,两者均随着病变的加重表达率明显增加,差异均有统计学意义（P〈0．001）。COX-2表达与VEGF呈显著正相关（P=0．001）。人乳头瘤病毒（HPV）在低度CIN、高度CIN及宫颈癌的感染率分别为30．77％、71．43％、100％,在宫颈癌及其癌前病变中,COX-2与高危HPV感染率呈正相关（P=0．021）。结论COX-2与宫颈癌的发生、发展有关,并可能与肿瘤的血管生成有密切的关系。COX-2可能成为宫颈癌早期防治的靶点。